Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24547737 | 0.86 | LMNA (0.50) | ELANEKMT2AP2RX4MAPTLMNA | |
| SCHEMBL24547742 | 0.86 | P2RX4 (0.56) | ELANEKMT2AP2RX4MAPTLMNA | |
| SCHEMBL24547736 | 0.84 | ELANE (0.52) | ELANEPARP1HPGDCES2CES1 | |
| SCHEMBL27112822 | 0.83 | ELANE (0.46) | ELANEKMT2AP2RX4MAPTLMNA | |
| SCHEMBL24547657 | 0.81 | LMNA (0.44) | ELANEKMT2AP2RX4MAPTLMNA | |
| SCHEMBL24547632 | 0.81 | P2RX4 (0.43) | KMT2AP2RX4MAPTLMNAHTT | |
| SCHEMBL24547630 | 0.80 | LMNA (0.48) | KMT2AP2RX4MAPTLMNAHTT | |
| SCHEMBL24547658 | 0.80 | LMNA (0.67) | ELANEKMT2AP2RX4MAPTLMNA | |
| SCHEMBL24547739 | 0.79 | KMT2A (0.49) | ELANEKMT2AMAPTLMNAHTT | |
| SCHEMBL24547661 | 0.79 | ABCB1 (0.50) | ELANEKMT2AP2RX4MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067654-A1 | OXYTOCIN RECEPTOR MODULATORS | Kinoxis Therapeutics Pty Ltd (AU) | 2024-02-29 | — | — | US | disclosed |
| US-20240067654-A1 | OXYTOCIN RECEPTOR MODULATORS | Kinoxis Therapeutics Pty Ltd (AU) | 2024-02-29 | — | — | US | disclosed |
| WO-2022126179-A1 | OXYTOCIN RECEPTOR MODULATORS | THE UNIVERSITY OF SYDNEY (AU) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067654-A1 | OXYTOCIN RECEPTOR MODULATORS | OXTR, AVPR1B, AVPR1A | ELANE 3651/4885KMT2A 4547/4885P2RX4 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.